Tags

Type your tag names separated by a space and hit enter

Opana ER abuse and thrombotic thrombocytopenic purpura (TTP)-like illness: a rising risk factor in illicit drug users.
BMJ Case Rep. 2014 Mar 03; 2014BC

Abstract

We report the case of a 22 year-old-woman who presented with upper extremity cellulitis secondary to an infiltration of illicit intravenous drug use. She confessed to the intravenous use of Opana ER (an extended release oral formulation of oxymorphone) which is an opioid drug approved only for oral use. She was found to have clinical evidence of profound thrombotic microangiopathy which resulted due to the intravenous use of Opana ER. She showed full clinical improvement after withholding drug and supportive clinical care. Recent report of Opana ER intravenous abuse was published from Tennessee county and has now been increasingly recognised as one of the causes of thrombocytopenia which mimicks clinically as thrombotic thrombocytopenic purpura. Physicians should be aware of this association as the lack of familiarity to this can pose serious management dilemmas for our patients (especially the polysubstance abusers).

Authors+Show Affiliations

Department of Internal Medicine, East Tennessee State University, Johnson City, Tennessee, USA.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Case Reports
Journal Article

Language

eng

PubMed ID

24591390

Citation

Kapila, Aaysha, et al. "Opana ER Abuse and Thrombotic Thrombocytopenic Purpura (TTP)-like Illness: a Rising Risk Factor in Illicit Drug Users." BMJ Case Reports, vol. 2014, 2014.
Kapila A, Chhabra L, Chaubey VK, et al. Opana ER abuse and thrombotic thrombocytopenic purpura (TTP)-like illness: a rising risk factor in illicit drug users. BMJ Case Rep. 2014;2014.
Kapila, A., Chhabra, L., Chaubey, V. K., & Summers, J. (2014). Opana ER abuse and thrombotic thrombocytopenic purpura (TTP)-like illness: a rising risk factor in illicit drug users. BMJ Case Reports, 2014. https://doi.org/10.1136/bcr-2013-203122
Kapila A, et al. Opana ER Abuse and Thrombotic Thrombocytopenic Purpura (TTP)-like Illness: a Rising Risk Factor in Illicit Drug Users. BMJ Case Rep. 2014 Mar 3;2014 PubMed PMID: 24591390.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Opana ER abuse and thrombotic thrombocytopenic purpura (TTP)-like illness: a rising risk factor in illicit drug users. AU - Kapila,Aaysha, AU - Chhabra,Lovely, AU - Chaubey,Vinod K, AU - Summers,Jeffery, Y1 - 2014/03/03/ PY - 2014/3/5/entrez PY - 2014/3/5/pubmed PY - 2015/1/23/medline JF - BMJ case reports JO - BMJ Case Rep VL - 2014 N2 - We report the case of a 22 year-old-woman who presented with upper extremity cellulitis secondary to an infiltration of illicit intravenous drug use. She confessed to the intravenous use of Opana ER (an extended release oral formulation of oxymorphone) which is an opioid drug approved only for oral use. She was found to have clinical evidence of profound thrombotic microangiopathy which resulted due to the intravenous use of Opana ER. She showed full clinical improvement after withholding drug and supportive clinical care. Recent report of Opana ER intravenous abuse was published from Tennessee county and has now been increasingly recognised as one of the causes of thrombocytopenia which mimicks clinically as thrombotic thrombocytopenic purpura. Physicians should be aware of this association as the lack of familiarity to this can pose serious management dilemmas for our patients (especially the polysubstance abusers). SN - 1757-790X UR - https://www.unboundmedicine.com/medline/citation/24591390/Opana_ER_abuse_and_thrombotic_thrombocytopenic_purpura__TTP__like_illness:_a_rising_risk_factor_in_illicit_drug_users_ L2 - https://casereports.bmj.com/cgi/pmidlookup?view=long&pmid=24591390 DB - PRIME DP - Unbound Medicine ER -